Connect with us

Health

Omni Health Inc (OTCMKTS:OMHE) Reported Advancement Of New Drug Candidate

Published

on

Omni Health Inc (OTCMKTS:OMHE) a vertically integrated healthcare firm committed to the advancement of pharmaceutical, anti-aging items, and biotech engineering, reported its plan already in place to establish a drug candidate captivating to Big Pharma.

The details

Grounded on four decades of standard care, Omni Health has commenced the procedure of reformulating its proprietary formularies to comprise cannabidiol and start its FDA Medical Devices enrollment for topical pain analgesic. It is company’s intent to capitalize on a considerable potential for cannabinoid bio therapeutics to revolutionize the treatment of chronic pain and other weakening conditions, and launch a product to the market with a robust demand and reimbursable under major insurance and government payors plans.

Andrey Soloviev, the CEO of Omni Health, expressed that by engaging an FDA regulations-savvy, fast-track pipeline plan, the company will fast be in a position to associate their new drug for late-phase advancement. Their estimations set this target date at around three years out. It will be a tough peer in a lucrative medicinal segment populated by a confined number of pain management offerings at exponentially higher valuations. Competitor analysis exhibits these valuations to stay in the range of $100 million – $140 Million.

In addition, Omni Health is in the final phases of advancement of non-prescription CBD analgesic ointments and creams with fast absorption properties which they are able to fast deploy to the market. Concurrent to the FDA filing for this new drug, the firm will start by manufacturing OTC analgesic ointments and creams containing CBD with optimal bioavailability and rapid absorption profiles.

Provided the strength of these analgesics, they will be distributed and marketed exclusively to doctors’ offices, hospitals and clinics to ensure appropriate product usage and patient support. As per the existing plan, it’s expected that this product will be launched to the North American market in Q3 2018. Based on competitor analysis and current market trends, Omni Health estimates generating a recurring yearly revenue surpassing $7 million.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of MMJReporter.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure

BRANDS

DETAILS

SCORE

PRODUCT SITES

  • Certified Organic
  • Made In U.S.A
  • Purity Promise
  • Price From $49

9.8

30% OFF Today! “30 0FF”

  • All Natural
  • Made In U.S.A
  • Lab Tested
  • Price From $69

9.7

  • All Natural
  • Made In U.S.A
  • Dissolvable Oral
  • Price From $99

9.6

  • All Natural
  • Made In U.S.A
  • Oral Mist
  • Price From $39

9.5

BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Purity Promise
  • Price From $49
SCORE

9.8

PRODUCT SITE
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Lab Tested
  • Price From $69
SCORE

9.7

PRODUCT SITE VIEW PRODUCTS
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Dissolvable Oral
  • Price From $99
SCORE

9.6

PRODUCT SITE VIEW PRODUCTS
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Oral Mist
  • Price From $39
SCORE

9.5

PRODUCT SITE VIEW PRODUCTS
Advertisement
Advertisement

Symbol        Alert        High        Gain

 

  VBIO          $0.67       $4.10      500%

  IMLFF        $0.11       $0.57      400%

  CMXC        $0.25       $0.45      80%

  REPCF       $0.54       $0.79      48%

 

Get Your Latest Winner Delivered to Your Inbox!

FREE

For The Next 48 Hours

Advertisement
Advertisement
Advertisement
Advertisement
Advertisement